Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with <i>TP53</i> ‐mutated acute myeloid leukemia-Reference-Cited by-同舟云学术

Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53 ‐mutated acute myeloid leukemia

Published:2022-12-21 Issue:6 Volume:129 Page:934-945
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Badar Talha¹^ORCID,Litzow Mark R.²,Shallis Rory M.³^ORCID,Patel Anand⁴^ORCID,Saliba Antoine N.²,Burkart Madelyn⁵^ORCID,Bewersdorf Jan P.⁶^ORCID,Stahl Maximilian⁴,De Camargo Correia Guilherme Sacchi¹,Guru Murthy Guru Subramanian⁷^ORCID,Abaza Yasmin⁵^ORCID,Duvall Adam⁴,Bradshaw Danielle⁸,Kota Vamsi⁸^ORCID,Dinner Shira⁵,Goldberg Aaron D.⁶,Palmisiano Neil⁹,Al Kali Aref²,Atallah Ehab¹⁰

Affiliation:

1. Division of Hematology and Medical Oncology Mayo Clinic Jacksonville Florida USA

2. Division of Hematology Mayo Clinic Rochester Minnesota USA

3. Section of Hematology Department of Internal Medicine Yale University School of Medicine New Haven Connecticut USA

4. Section of Hematology and Oncology Department of Medicine University of Chicago Chicago Illinois USA

5. Robert H. Lurie Comprehensive Cancer Center Northwestern Hospital Chicago Illinois USA

6. Division of Hematologic Malignancies Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

7. Department of Hematology Dana‐Farber Cancer Institute Boston Massachusetts USA

8. Division of Hematology and Medical Oncology Georgia Cancer Center Augusta Georgia USA

9. Division of Hematology and Oncology Jefferson University Hospital Philadelphia Pennsylvania USA

10. Division of Hematology and Medical Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34604

Reference18 articles.

1. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

2. TP53mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

3. Outcomes of TP53 ‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in acute myeloid leukemia treatments and outcomes;Current Opinion in Hematology;2023-12-07

2. Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?;Expert Review of Hematology;2023-10-27

3. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions;eJHaem;2023-09-11